InvestorsObserver is giving Esperion Therapeutics Inc (ESPR) an Analyst Rating Rank of 24, meaning ESPR is ranked higher by analysts than 24% of stocks. The average price target for ESPR is $11.555 and analyst’s rate the stock as a Buy.
Wall Street analysts are rating ESPR a Buy today. Find out what this means to you and get the rest of the rankings on ESPR!